Affinity reports 5.5% stake in Avalo Therapeutics

Avalo Therapeutics reports that Affinity Asset Advisors, LLC and Michael Cho beneficially own 1,340,840 shares of Common Stock as of March 31, 2026.

Rhea-AI Filing Summary

Avalo Therapeutics reports that Affinity Asset Advisors, LLC and Michael Cho beneficially own 1,340,840 shares of Common Stock as of March 31, 2026. This position represents approximately 5.5% of the company's Common Stock based on 24,502,449 shares outstanding as of March 26, 2026. The filing states the shares are directly held by Affinity Healthcare Fund, LP, with the Adviser exercising sole voting and dispositive power over those shares.

Insights

Corporate Governance Specialist

Affinity and its manager report a 5.5% beneficial stake in Avalo Therapeutics.

The filing shows 1,340,840 shares beneficially owned as of March 31, 2026, with sole voting and dispositive power vested in Affinity Asset Advisors under an investment management agreement. The position is reported via an amended Schedule 13G/A.

Share-count anchors include the issuer's stated outstanding share base of 24,502,449 shares as of March 26, 2026. Subsequent disclosures may show changes; the filing itself does not state any planned transactions.

Securities Compliance Attorney

The amendment clarifies beneficial ownership and voting/dispositive authority.

The Adviser is described as investment manager of the Fund and may be deemed a beneficial owner; Michael Cho is identified as the managing member. The filing attributes sole voting and dispositive powers to the Reporting Persons for the full share count.

Reporting dates and the proxy-statement outstanding-share figure are explicitly cited; filings required by Section 13 remain the primary source for any changes.

Key Figures

Beneficial ownership: 1,340,840 shares Percent of class: 5.5% Shares outstanding used: 24,502,449 shares

3 metrics

Beneficial ownership 1,340,840 shares As of March 31, 2026

Percent of class 5.5% Based on 24,502,449 shares outstanding as of March 26, 2026

Shares outstanding used 24,502,449 shares Outstanding as of March 26, 2026 per issuer proxy statement

Key Terms

beneficially own, sole dispositive power, Schedule 13G/A

3 terms

beneficially own regulatory

"the Adviser and Mr. Cho beneficially own 1,340,840 shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole dispositive power regulatory

"sole power to dispose or to direct the disposition of 1,340,840 shares"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G/A regulatory

"Amendment No. 3 and Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Affinity Asset Advisors report in Avalo Therapeutics (AVTX)?

Affinity Asset Advisors and Michael Cho report beneficial ownership of 1,340,840 shares as of March 31, 2026, representing 5.5% of Common Stock based on 24,502,449 shares outstanding as of March 26, 2026.

Who holds voting and dispositive power over the reported AVTX shares?

The filing states the shares are directly held by Affinity Healthcare Fund, LP, and Affinity Asset Advisors, LLC exercises sole voting and dispositive power over those shares pursuant to an investment management agreement.

Are the reported AVTX shares owned directly by Michael Cho?

The filing explains the shares are held directly by the Fund; Michael Cho, as managing member of the Adviser, may be deemed a beneficial owner but the shares are reported as directly held by the Fund.

What source does the filing use for shares outstanding for AVTX?

The percentage calculation uses 24,502,449 shares outstanding cited from the issuer's Definitive Proxy Statement filed on April 10, 2026, with the outstanding count dated March 26, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:09 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Avalo Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

05338F306

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Affinity Asset Advisors, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,340,840.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,340,840.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,340,840.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Michael Cho

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,340,840.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,340,840.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,340,840.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IN, HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Avalo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania, 19087
Item 2.
(a)	Name of person filing: Affinity Asset Advisors, LLC Michael Cho
(b)	Address or principal business office or, if none, residence: 450 Park Avenue Suite 1403 New York, NY 10022
(c)	Citizenship: Affinity Asset Advisors, LLC is a Delaware limited liability company, and Michael Cho is an individual and is a citizen of the United States.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 05338F306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The securities reported herein are directly held by Affinity Healthcare Fund, LP (the "Fund"). Affinity Asset Advisors, LLC (the "Adviser") is the investment manager of the Fund and exercises voting and investment power over the securities held directly by the Fund reported herein pursuant to an investment management agreement between the Adviser, the Fund, and the general partner of the Fund. The Adviser may be deemed to beneficially own the securities reported herein held by the Fund by virtue of its position as investment manager of the Fund. Michael Cho, the managing member of the Adviser, may be deemed a beneficial owner of the securities reported herein held directly by the Fund. As of March 31, 2026, the Adviser and Mr. Cho (collectively, the "Reporting Persons") beneficially own 1,340,840 shares of common Stock, $0.001 par value per share ("Common Stock"), of Avalo Therapeutics, Inc. (the "Issuer").
(b)	Percent of class: As of March 31, 2026, the Reporting Persons beneficially own approximately 5.5% of the Common Stock outstanding. The percentages disclosed above are based on 24,502,449 shares of Common Stock of the Issuer outstanding as of March 26, 2026, as set forth in the Issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 10, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: As of March 31, 2026, the Reporting Persons have sole power to vote or to direct the vote of 1,340,840 shares of Common Stock.
	(ii) Shared power to vote or to direct the vote: As of March 31, 2026, the Reporting Persons have shared power to vote or to direct the vote of 0 shares of Common Stock.
	(iii) Sole power to dispose or to direct the disposition of: As of March 31, 2026, the Reporting Persons have sole power to dispose or to direct the disposition of 1,340,840 shares of Common Stock.
	(iv) Shared power to dispose or to direct the disposition of: As of March 31, 2026, the Reporting Persons have shared power to dispose or to direct the disposition of 0 shares of Common Stock.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Affinity Asset Advisors, LLC

Signature:	/s/ Andrew Weinstein
Name/Title:	Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
Date:	05/14/2026

Michael Cho

Signature:	/s/ Michael Cho
Name/Title:	Michael Cho, Self
Date:	05/14/2026